The compound appears to cause complete remission in patients with small-cell lung cancer or other CD56-expressing solid tumors, lasting at least 15 weeks, and disease stability lasting up to 18 weeks, the Cambridge, Mass.-based firm said in a statement.
ImmunoGen presented its Phase 1 clinical findings on the tumor-activated prodrug compound at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.
In the ongoing trial, the drug is being administered daily for three consecutive days in a 21-day cycle to patients with CD56-expressing solid tumors, ImmunoGen said.
New cohorts of patients receive progressively higher doses of huN901-DM1 until the maximum tolerated dose is established, the company said.
All study patients have relapsed or refractory small-cell lung cancer (SCLC) or other CD56-expressing solid tumors.